Remission of aHUS neurological damage with eculizumab

Clinical Kidney Journal

Volumn 8, Issue 2, 2015, Pages 232-236

  Ávila, Ana ^a   Vizcaíno, Belén ^a   Molina, Pablo ^a   Gavela, Eva ^a   Perez Ebri, Maria ^a   Pallardó, Luís ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Atypical haemolytic uraemic syndrome; Eculizumab; Neurologic involvement; Plasma exchange; Thrombotic microangiopathy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECULIZUMAB; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENICILLIN DERIVATIVE;

ACUTE KIDNEY FAILURE; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRAIN ATROPHY; CASE REPORT; CHRONIC DISEASE; CONVALESCENCE; CREATININE BLOOD LEVEL; DIAGNOSTIC ERROR; DIALYSIS; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTENSION RETINOPATHY; HYPERURICEMIA; IMMUNOFLUORESCENCE; KIDNEY BIOPSY; LACTATE DEHYDROGENASE BLOOD LEVEL; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOSCOPY; PLASMAPHERESIS; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; REMISSION; THERAPY RESISTANCE; THROMBOCYTOPENIA; VACCINATION; WHITE MATTER LESION;

EID: 84942102372     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu144     Document Type: Article

References (25)

1. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687
2. Loirat C, Frémeaux-Bacchi V. Atypical haemolytic uremic syndrome. Orphanet J Rare Dis 2011; 6: 60
3. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554-562
4. Lemaire M, Frémeaux-Bacchi V, Schaeffer K et al. Recessive mutations in DKGE cause atypical haemolytic uremic syndrome. Nat Genet 2013; 45: 531-536
5. Menni F, Testa S, Guez S. Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria. Pediatr Nephrol 2012; 27: 1401-1405
6. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008; 23: 1957-1972
7. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al. Differential impact of complement mutations on clinical characteristics in atypicalhemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-2400
8. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-633
9. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181
10. Manenti L, Gnappi E, Vaglio A et al. Atypical haemolyticuraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol Dial Transplant 2013; 28: 2246-2259
11. Wada T, Nangaku M. Novel roles of complement in renal diseases and their therapeutic consequences. Kidney Int 2013; 84: 441-450
12. Satchell S. The role of the glomerular endothelium in albumin handling. Nat Rev Nephrol 2013; 9: 717-725
13. Tkaczyk M, Czupryniak A, Owczarek D et al. Markers of endothelial dysfunction in children with idiopathic nephrotic syndrome. Am J Nephrol 2008; 28: 197-202
14. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136
15. Sethi S, Fervenza F, Zhang Y et al. Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement Factor H and C3. Am J Kidney Dis 2012; 60: 316-321
16. Strassheim D, Renner B, Panzer S et al. IgM contributes to glomerular injury in FSGS. J Am Soc Nephrol 2013; 24: 393-406
17. Caprioli J, Noris M, Brioschi S et al. The International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279
18. Greenbaum LA, Fila M, Tsimaratos M et al. Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric atypical hemolytic uremic syndrome patients [abstract]. In: XXIII ASN Kidney Week. Abstract SA-PO849, 2013 Nov 5-10, p. 821A. American Society of Nephrology kidney Week, Atlanta, GA, 2013
19. Fakhouri F, Hourmant M, Campistol JM et al. Eculizumab inhibits thrombotic microangiopathy and improves renal function in adult patients with atypical hemolytic uremic syndrome [abstract]. In: America Society of Nephrology Kidney Week. Abstract FR-OR05, 2013 Nov 5-10, p. 49A-50-A. ASN Kidney Week, Atlanta, GA, 2013
20. Povey H, Vundru R, Junglee N et al. Renal recovery with eculizumab in atypicalhemolytic uremic syndrome following prolonged dialysis. Clin Nephrol 2013
21. Békássy ZD, Kristoffersson AC, Cronqvist M et al. Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrol Dial Transplant 2013; 28: 2899-2907
22. Salem G, Flynn JM, Cataland SR. Profound neurological injury in a patient with atypical haemolytic uremic syndrome. Ann Hematol 2013; 92: 557-558
23. Dorresteijn EM, van de Kar NC, Cransberg K. Eculizumab as rescue therapy for atypicalhemolytic uremic syndrome with normal platelet count. Pediatr Nephrol 2012; 27: 1193-1195
24. Hu H, Nagra A, Haq MR et al. Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement. Pediatr Nephrol 2014; 29: 1103-1106
25. Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 2011; 3: 5-12